Introduction The immunosuppressive enzyme, indoleamine 2,3 dioxygenase (IDO), is overexpressed in many different tumor types including breast cancer. IDO inhibitors synergize with chemotherapy in breast cancer murine models. Characterizing IDO expression in breast cancer could define which patients receive IDO inhibitors. This study analyzed IDO protein expression in 203 breast cancer cases. The relationship between IDO, overall survival (OS), disease-specific survival (DSS), clinicopathologic, molecular, and immune tumor infiltrate factors was evaluated. Methods Expression of IDO, estrogen receptor (ER), progesterone receptor (PR), human epithelial receptor 2, cytokeratin 5/6, epithelial growth factor receptor, phosphorylated AKT, neoangiogenesis, nitrogen oxide synthetase 2 (NOS2), cyclooxygenase 2 (COX2), FoxP3, CD8, and CD11b on archival breast cancer tissue sections was evaluated by immunohistochemistry. Associations between IDO and these markers were explored by a univariate and multivariate analysis. Survival was analyzed using KaplanMeier (OS) and Wilcoxon two-sample (DSS) tests.
Introduction
The inducible enzyme known as indoleamine 2,3 dioxygenase (IDO or IDO1) and a splice variant of IDO known as IDO2 participate in the catabolism of tryptophan that generates various biologically active and immunosuppressive metabolites such as kynurenine [1] . The role of IDO in immunosuppression was revealed by Munn et al. [2] who showed that IDO can prevent immune rejection and spontaneous abortion of allogeneic concepti. The finding sparked a great deal of ongoing research into the role of IDO in autoimmunity, graft rejection, and tumor-mediated immunosuppression [3] [4] [5] . Many different tumor types overexpress IDO in response to cytokines such as interferon-c, and the subsequent breakdown of tryptophan into various metabolites such as kynurenine causes tumor-infiltrating lymphocytes to become anergic and die [6] [7] [8] [9] [10] . Studies looking at IDO expression in ovarian, endometrial, and colorectal cancer have shown that high IDO expression is correlated with poorer outcomes [11] [12] [13] . In colorectal cancer, there was no survival difference seen, but high IDO-expressing tumors were more likely to metastasize to the liver. There is evidence that combining IDO inhibitors can synergize with various chemotherapeutic agents in a MMTV-neu murine model [14] . Chemotherapy agents such as taxanes induce an influx of tumor-infiltrating lymphocytes (TILs) in breast tumors. Using an IDO inhibitor in combination with a taxane may augment the ability of the TILs to kill tumor cells and improve clinical response. This approach is currently the subject of a phase I clinical trial in metastatic solid tumors, so understanding which breast cancers overexpress IDO is particularly relevant.
A recently published study analyzing IDO expression in 26 breast cancer cases correlated higher IDO expression with a lymph node involvement and a non-significant trend toward worse recurrence-free survival [15] . Interestingly, another recent study published by Jaquemiere et al. [16] demonstrated elevated INDO mRNA transcript levels and IDO protein in a subset of triple-negative basal breast cancers. This was particularly evident in the medullary subtype. In addition, increased IDO was associated with a favorable prognosis and lack of nodal involvement in their dataset. Due to these conflicting results, we sought to investigate whether we could confirm any of the prior clinicopathologic associations with IDO expression. We also wanted to explore any relationships between IDO expression and other molecular factors including ER, PR, epithelial receptor 2 (HER2), basal breast cancer markers (CK5/6 and EGFR), phosphorylation of AKT (pAKT473), caspase 9 activity, and neoangiogenesis (CD31). Finally, the impact of IDO expression on FoxP3? (T-regulatory cells), CD11b? (macrophages, granulocytes, natural killer cells), CD8? (Th1 cytotoxic T cells) immune cell tumor infiltrates, cyclooxygenase-2 (COX2), and nitrogen oxide synthetase (NOS2) was evaluated.
Materials and methods

Collection of tumor specimens and survival information
For this retrospective analysis, paraffin-embedded tumor specimens were obtained from 203 breast cancer patients that resided in the greater Baltimore area, as described [17] . Patients were recruited at the University of Maryland Medical Center (UMD), the Baltimore Veterans Affairs Medical Center, Union Memorial Hospital, Mercy Medical Center, and the Sinai Hospital in Baltimore between 1993 and 2003 as part of a molecular epidemiology study that examines markers for cancer risk and disease outcome in breast cancer [18] . All patients were identified through surgery lists and enrolled into the study prior to surgery. They signed a consent form for the unspecified use of biospecimens and survey data in research studies of breast cancer and completed an interviewer-administered questionnaire. Cases were eligible if they resided in the greater Baltimore area at the time of recruitment, were of African American or Caucasian descent by self-report, had pathologically confirmed breast cancer, were diagnosed with breast cancer within the last 6 months prior to recruitment, and had no previous history of breast cancer. Patients were excluded if they were HIV, HCV, or HBV carriers, were IV-drug users, were institutionalized, or were physically or mentally unable to sign consent and complete the questionnaire. Clinical and pathological information was obtained from medical records and pathology reports. Disease staging was performed according to the tumornode-metastasis (TNM) system of the American Joint Committee on Cancer/the Union Internationale Contre le Cancer (AJCC/UICC). The Nottingham system was used to determine the tumor grade. Survival was determined for the period from the date of hospital admission to the date of the last completed search for death entries in the Social Security Index (date of search: December 31st, 2006) for the 203 patients. The mean and median follow-up times for breast cancer survival were 71 and 68 months, respectively (range: 12-166 months). We obtained information (National Death Index, death certificates) on the causes of death for the deceased patients and censored all patients whose causes of death, such as accidents, were not related to breast cancer (n = 11). The collection of tumor specimens, survey data, and clinical and pathological information, and follow-up data was reviewed and approved by the University of Maryland Institutional Review Board for the participating institutions (UMD protocol #0298229). IRB approval of this protocol was then obtained at all institutions (Veterans Affairs Medical Center, Union Memorial Hospital, Mercy Medical Center, and Sinai Hospital). The research was also reviewed and approved by the NIH Office of Human Subjects Research (OHSR #2248) and University of South Florida IRB (MCC16015).
Immunohistochemical staining and scoring of IDO Slides were stained using a Ventana Discovery XT automated system (Ventana Medical Systems, Tucson) as per manufacturer's protocol with proprietary reagents. Briefly, slides were deparaffinized on the automated system with EZ Prep solution (Ventana). Enzymatic retrieval method was used in protease 1 at 4 min (Ventana). The mouse primary antibody that reacts to IDO1 (#mab5412, Millipore, Temecula, CA, USA) was used at a 1:50 concentration in Dako antibody diluent (Carpenteria, CA, USA) and incubated for 60 min. The Ventana anti-mouse secondary antibody was used for 16 min. IDO labeling was visualized using the Ventana OmniMap kit and slides were then counterstained with hematoxylin. Slides were then dehydrated and coverslipped as per normal laboratory protocol. The slides were scored numerically by two pathologists on intensity of IDO cytoplasmic staining (0, 1, 2, 3) and percent cells staining positive (0 = 0 %, 1 = 1-33 %, 2 = 34-66 %, 3 C 66 %). The slides also underwent computer image analysis for IDO staining as an additional quality assurance measure (Analytic Microscopy Core, Moffitt Cancer Center). Differences in scores were adjudicated between the two pathologists to arrive at a final score. The product of the two values would result in a composite IDO score, and the scores were stratified as low = 0-2, intermediate = 3 and 4, and high = 6 and 9. For all statistical and survival analyses, the samples were grouped into either IDO-low (0-2) or IDO-medium/high (3, 4, 6, 9) groups.
Immunohistochemical staining and evaluation for all other markers including COX2, NOS2, and tumor immune infiltrates
The staining and quantification method for the various proteins analyzed in this dataset including ER, PR, HER2, AKT, COX2, EGFR, CK5/6, and NOS2 was previously published [17, 19] . Immune infiltrates were characterized utilizing Ab-3 antibody (Lab Vision Corp.) for CD68 at 1:250; (no. 2729-1; Epitomics) for CD11b at 1:1,000; for FoxP3 1:1,500 diluted rabbit polyclonal antibody (Abcam); CD8 1:100 mouse monoclonal antibody (Thermo Fisher scientific). Immunostaining was detected with Dako Envision System kits after standard deparaffinization and citrate buffer antigen retrieval. Counterstaining with methyl green was used for all markers with the exception of CD11b? (hematoxylin and Tacha's bluing solution). The cell counts analyzed were an average of three high-powered fields.
Statistical analysis
Descriptive statistics for patient and tumor characteristics were presented overall and by IDO scores (low vs. medium/ high). Comparisons between IDO scores and patient and tumor characteristics were made using the exact Wilcoxon Rank Sum test for continuous characteristics, and the exact Pearson Chi-squared test for categorical characteristics, both using Monte Carlo estimation. The logistic regression model was used to assess univariate association between IDO scores (medium/high vs. low) and patients or tumor characteristics. The variables that were significantly associated with IDO scores in univariate analysis were then simultaneously put in multivariate logistic regression model to assess the association while adjusting for other significantly associated variables. No adjustment for multiple testing was performed in this exploratory analysis. Overall survival (OS) was examined using Kaplan-Meier survival curves with log-rank test. All p values are two-sided and considered statistically significant at the 0.05 level. All statistical analyses were performed using SAS (version 9.3; SAS Institute; Cary, NC, USA).
Results
Demographics, pathologic factors, and treatment information
The patient demographics and characteristics are summarized in Table 1 . The overall median age was 54 (range 29-93), and all participants were female. Approximately 61 % were African American in keeping with the catchment area served by the participating hospitals involved. The stage distribution was typical with 7.3, 21.3, 56.7, 20.2, and 1.7 % presenting with Stage 0, I, II, III, and IV, respectively. The frequency of ER-positive disease was 61.6 and 55.2 % of thes patient in the study received adjuvant chemotherapy. In the analysis of categorical variables, it appears that smaller, node-negative breast cancers had higher IDO expression compared to more advanced stages. Tumors with higher p-caspase 9, EGFR, NOS2, and COX2 expression also had higher IDO levels. The data regarding EGFR are less robust due to a large number of missing EGFR scores for this dataset. Finally, an inverse relationship was noted between CD31 and IDO expression.
Survival analysis
Overall survival (OS) was compared between the IDO-low and IDO-medium/high groups. There was no statistically significant difference between the two groups across all patients in the sample (5-year OS 78 vs. 67 %, p = 0.248) (Fig. 1) . However, subset analysis revealed that within the ER-positive subgroup, patients with medium/high IDO expression had a superior OS compared to IDO low (5-year OS 86 vs. 65 %, p = 0.0215) (Fig. 2) . Disease-specific survival (DSS) trended toward superiority in IDO medium/ high versus IDO low (mean DSS 35.5 vs. 27.1 months, p = 0.068). In addition, DSS within the node-positive group was superior for IDO-medium/high compared to IDO-low tumors (mean DSS 23.5 vs. 15.4 months, p = 0.03). There were no other survival differences observed within other clinical subsets between IDO-low versus IDO-medium/high groups. 
IDO staining results
None of the breast cancer specimens were completely negative for IDO staining. The mean value was 2.5, median and mode equaled 2, and range was 1-9. Out of 203 samples, 108 (53.2 %), 84 (41.4 %), and 11 (5.4 %) had a low, medium, and high IDO score, respectively. The staining was cytoplasmic as was expected and was mainly confined to the malignant ductal cells and mostly undetectable in the adjacent stromal cells (Fig. 3) . However, there were occasional mononuclear cells that stained positive for IDO infiltrating the surrounding tumor stroma. The distribution of IDO scores across the study population is shown in a histogram (Fig. 4) .
Interobserver concordance between the two pathologists and computer-aided image analysis for IDO score stratification was [90 % demonstrating reproducibility of the IHC analysis.
Univariate and multivariate analysis (Fig. 5 ).
Conclusions
The findings from this study support the observation that higher IDO expression is associated with a better survival outcome, consistent with the findings published by Jaquemiere et al. However, we observed this association in ER? and node-positive breast cancers but not in ER-disease.
Due to the multiple analyses conducted, these findings are hypothesis generating and should be confirmed in other datasets. Although both studies associated elevated IDO with a favorable outcome, we observed elevated IDO in different histological and biologic subtypes than Jaquemiere et al. Their study included a large sample size and reasonable study methodology, but primarily analyzed IDO expression at the RNA level while we studied IDO protein expression in archived tissues. Additional research is required to reconcile the differences between the two studies, but it is known that IDO mRNA expression can be divergent from IDO protein expression due to multiple transcriptional control mechanisms. It is for this reason that we feel measurement of IDO protein may serve as a more reliable means to study the activation of this pathway in relation to other biologic factors. Our study shows that IDO-low-expressing tumors were more frequently estrogen-receptor-negative with greater neovascularization. The other interesting finding is that higher IDO expression levels correlated with higher expression of other inflammatory markers like NOS2 in breast tumors. It has been shown in the past that both IDO and NOS2 are interferoninducible enzymes which may explain their co-expression in a subset of breast tumors. There is in vitro fibroblast cell line data suggesting that nitric oxide exerts a post-translational inhibitory effect on IDO [20] . While COX2 appeared to positively trend with IDO expression, this could not be confirmed on the multivariate analysis and may require a larger dataset to assess this. Understanding the interplay between these enzymes in experimental breast cancer models could lead to better understanding on how functionally active IDO is and how to manipulate them for maximal immunotherapeutic benefit. Additional analyses could not link IDO expression to the number of tumorinfiltrating T-regulatory and cytotoxic T cells in these breast tumors. However, low IDO expression was found to correlate with increased CD11b? tumor infiltrates. This preliminary finding, however, will require further confirmation.
Why an immunosuppressive enzyme like IDO could lead to a favorable survival outcome in breast cancer is unknown. It may be that increased IDO activation may lead to a metabolic growth disadvantage due to decreased tryptophan within the tumor microenvironment. The inverse association observed between IDO expression and CD11b? macrophages is another possibility, as CD11b? macrophages have been associated with facilitating tumor progression in murine breast cancer models [21] . The pathologic activation of IDO in tumors is only part of a complex web of interconnected metabolic and immune regulatory pathways. It is possible that IDO activation can facilitate or hinder tumor progression in a host. The degree to which it does either may be influenced by other specific host conditions, type of cancer, or stage the malignancy is in. Understanding the role of IDO in the natural progression of breast cancer through various stages and in different scenarios will be important to determine the optimal targeting of this pathway. Our data suggests that future trials of IDO inhibitors combined with chemotherapy must take into account the proper stratification of biologic subtypes across study treatment arms. This information will better inform clinicians on how to integrate IDO inhibitors currently undergoing clinical trials in the treatment of breast cancer.
